Clinical Trials on SCLC

Total 1095 results

Sun Yat-sen University

Not yet recruiting

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NSCLC | BRAF V600 Mutation | MET Exon 14 Mutation

China
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer (NSCLC)

NSCLC
Peking Union Medical College

Recruiting

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）

NSCLC | Brain Metastases | Furmonertinib | EGFR-mutation

China
Institut Curie

Recruiting

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG (LIBERTYLUNG)

NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor

France
Greg Durm, MD
Merck Sharp & Dohme LLC

Recruiting

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

NSCLC, Stage I

United States
Xinqiao Hospital of Chongqing

Completed

Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)

Advanced Nsclc

China
Tianjin Medical University Cancer Institute and...
Tianjin Medical University General Hospital; Tianjin Chest Hospital

Completed

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Delirium | Analgesia | NSCLC | Immunotherapy

China
BerGenBio ASA
Merck Sharp & Dohme LLC

Completed

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Lung Cancer Metastatic | Adenocarcinoma of Lung | NSCLC Stage IV

United States, Spain, United Kingdom, Norway
Xiaolong Yan, Dr.

Enrolling by invitation

Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study

NSCLC, Stage I

China
CHU de Reims

Completed

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed (IPPEM)

Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy

France
Royal Marsden NHS Foundation Trust
Boehringer Ingelheim; Celgene

Withdrawn

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma (N3)

Adenocarcinoma of Lung | NSCLC, Recurrent
Allist Pharmaceuticals, Inc.

Unknown

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Advanced NSCLC

China
Hadassah Medical Organization

Unknown

Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)

NSCLC
Yuhan Corporation
The Korean Academy of Tuberculosis and Respiratory Diseases

Recruiting

Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation

NSCLC

Korea, Republic of
Peking University Cancer Hospital & Institute
Geneplus-Beijing Co. Ltd.

Recruiting

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer (MRDinS3LC)

NSCLC

China
Hunan Province Tumor Hospital

Not yet recruiting

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NSCLC

China
Shanghai Chest Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

NSCLC

China
Oslo University Hospital
St. Olavs Hospital

Recruiting

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients (Oncomabs)

NSCLC

Norway
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

NSCLC
Kura Oncology, Inc.

Withdrawn

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

NSCLC

United States
Qian Chu

Completed

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

NSCLC

China
University of Cologne
Pfizer; Spanish Lung Cancer Group

Completed

EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (EUCROSS)

Adenocarcinoma | NSCLC | Lung Cancer

Germany, Spain, Switzerland
Hutchison Medipharma Limited

Completed

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (FALUCA)

NSCLC

China
Guangdong Association of Clinical Trials

Unknown

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Advanced Non-squamous NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE)

NSCLC

China
Shanghai Chest Hospital

Unknown

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

NSCLC

China
GlobeImmune
Memorial Sloan Kettering Cancer Center

Completed

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

NSCLC

United States
Sheba Medical Center

Unknown

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NSCLC

Israel
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NSCLC

United States
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Sichuan University

Recruiting

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose Radiotherapy

China
Jianxing He

Not yet recruiting

Uniportal Tubeless VATS for the Evaluation of Biopsy for Second-generation Sequencing in Patients With Advanced NSCLC

NSCLC | VATS | Biopsy Technique | CT Guided Puncture Biopsy | NGS
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Advanced or Metastatic NSCLC

United States, Spain, Taiwan, Japan, Italy
The Fourth Affiliated Hospital of Zhejiang University...

Completed

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

NSCLC | EGFR Gene Mutation | Non-small-lung-cell Cancer

China
Beta Pharma Shanghai

Active, not recruiting

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

NSCLC

China
Armando Santoro, MD

Terminated

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients

NSCLC

Italy
Eli Lilly and Company
Celgene

Completed

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

United States
Allist Pharmaceuticals, Inc.

Unknown

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Advanced NSCLC Patients With T790M

China
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

NSCLC | Solid Tumors

United States
Amsterdam UMC, location VUmc

Unknown

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

NSCLC | EGFR-mutation | HER2-expression

Netherlands
Fudan University

Recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Maastricht University

Not yet recruiting

Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2 (I-SABR2_PDA)

Lung Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | NSCLC Stage IV
NovoCure GmbH

Active, not recruiting

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NSCLC | Nonsmall Cell Lung Cancer

United States, Poland, Hong Kong, China, Spain, Serbia, Croatia, France, Canada, Netherlands, Austria, Belgium, Bulgaria, Czechia, Germany, Hungary, Italy, Switzerland
Boryung Pharmaceutical Co., Ltd

Completed

Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor (DETECT)

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | NSCLC | Prostate Cancer

Korea, Republic of
Genzyme, a Sanofi Company

Completed

Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

NSCLC

Korea, Republic of
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Shanghai Zhongshan Hospital

Not yet recruiting

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer (WUKONG-9)

NSCLC
Amphia Hospital
Albert Schweitzer Hospital

Recruiting

Folinic Acid for Prevention of Pemetrexed-induced Toxicity (FLEX)

NSCLC | Thymoma | Mesothelioma

Netherlands

3

Subscribe